424 related articles for article (PubMed ID: 15894653)
1. Hormone replacement therapy, percent mammographic density, and sensitivity of mammography.
Kavanagh AM; Cawson J; Byrnes GB; Giles GG; Marr G; Tong B; Gertig DM; Hopper JL
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1060-4. PubMed ID: 15894653
[TBL] [Abstract][Full Text] [Related]
2. Hormone replacement therapy and accuracy of mammographic screening.
Kavanagh AM; Mitchell H; Giles GG
Lancet; 2000 Jan; 355(9200):270-4. PubMed ID: 10675074
[TBL] [Abstract][Full Text] [Related]
3. Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection.
Chiarelli AM; Kirsh VA; Klar NS; Shumak R; Jong R; Fishell E; Yaffe MJ; Boyd NF
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1856-62. PubMed ID: 17035392
[TBL] [Abstract][Full Text] [Related]
4. Hormone replacement therapy and mammographic screening outcomes in Western Australia.
Crouchley K; Wylie E; Khong E
J Med Screen; 2006; 13(2):93-7. PubMed ID: 16792833
[TBL] [Abstract][Full Text] [Related]
5. Risk factors and tumor characteristics of interval cancers by mammographic density.
Holm J; Humphreys K; Li J; Ploner A; Cheddad A; Eriksson M; Törnberg S; Hall P; Czene K
J Clin Oncol; 2015 Mar; 33(9):1030-7. PubMed ID: 25646195
[TBL] [Abstract][Full Text] [Related]
6. The sensitivity, specificity, and positive predictive value of screening mammography and symptomatic status.
Kavanagh AM; Giles GG; Mitchell H; Cawson JN
J Med Screen; 2000; 7(2):105-10. PubMed ID: 11002452
[TBL] [Abstract][Full Text] [Related]
7. Case-control study of increased mammographic breast density response to hormone replacement therapy.
Vachon CM; Sellers TA; Vierkant RA; Wu FF; Brandt KR
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1382-8. PubMed ID: 12433715
[TBL] [Abstract][Full Text] [Related]
8. Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect.
Banks E; Reeves G; Beral V; Bull D; Crossley B; Simmonds M; Hilton E; Bailey S; Barrett N; Briers P; English R; Jackson A; Kutt E; Lavelle J; Rockall L; Wallis MG; Wilson M; Patnick J
Breast Cancer Res; 2006; 8(1):R8. PubMed ID: 16417651
[TBL] [Abstract][Full Text] [Related]
9. Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens.
Hofvind S; Møller B; Thoresen S; Ursin G
Int J Cancer; 2006 Jun; 118(12):3112-7. PubMed ID: 16395702
[TBL] [Abstract][Full Text] [Related]
10. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography.
Laya MB; Larson EB; Taplin SH; White E
J Natl Cancer Inst; 1996 May; 88(10):643-9. PubMed ID: 8627640
[TBL] [Abstract][Full Text] [Related]
11. Does a short cessation of HRT decrease mammographic density?
Weaver K; Kataoka M; Murray J; Muir B; Anderson E; Warren R; Warsi I; Highnam R; Glasier A
Maturitas; 2008 Apr; 59(4):315-22. PubMed ID: 18448281
[TBL] [Abstract][Full Text] [Related]
12. Factors contributing to mammography failure in women aged 40-49 years.
Buist DS; Porter PL; Lehman C; Taplin SH; White E
J Natl Cancer Inst; 2004 Oct; 96(19):1432-40. PubMed ID: 15467032
[TBL] [Abstract][Full Text] [Related]
13. Mammographic density in women on postmenopausal hormone replacement therapy.
Leung W; Goldberg F; Zee B; Sterns E
Surgery; 1997 Oct; 122(4):669-73; discussion 673-4. PubMed ID: 9347841
[TBL] [Abstract][Full Text] [Related]
14. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
[TBL] [Abstract][Full Text] [Related]
15. Does a better grade of tumour occurring in women under hormone replacement therapy compensate for their lower probability of detection by screening mammography.
Estève J; Séradour B; Jacquemier J; Remontet L
J Med Screen; 2002; 9(2):70-3. PubMed ID: 12133926
[TBL] [Abstract][Full Text] [Related]
16. [Breast density: a major parameter to follow during hormone replacement therapy].
Gairard B; Guldenfels C; Haehnel P; Mathelin C
Gynecol Obstet Fertil; 2009; 37(7-8):657-60. PubMed ID: 19577502
[TBL] [Abstract][Full Text] [Related]
17. Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review.
Banks E
J Med Screen; 2001; 8(1):29-34. PubMed ID: 11373847
[TBL] [Abstract][Full Text] [Related]
18. Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density.
Persson I; Thurfjell E; Holmberg L
J Clin Oncol; 1997 Oct; 15(10):3201-7. PubMed ID: 9336356
[TBL] [Abstract][Full Text] [Related]
19. Determinants of false positive recall in an Australian mammographic screening program.
Kavanagh AM; Davidson N; Jolley D; Heuzenroeder L; Chapman A; Evans J; Gertig DM; Amos A
Breast; 2006 Aug; 15(4):510-8. PubMed ID: 16278082
[TBL] [Abstract][Full Text] [Related]
20. Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens.
Lundström E; Wilczek B; von Palffy Z; Söderqvist G; von Schoultz B
Climacteric; 2001 Mar; 4(1):42-8. PubMed ID: 11379377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
